As reported by The Financial Times, Sir Demis Hassabis, the founder of Isomorphic Labs, a drug discovery start-up owned by Google’s parent company Alphabet, announced that the company plans to have its first AI-designed drug in clinical trials by the end of 2025. The drug, which is being developed using advanced artificial intelligence, will focus on critical areas in medical research such as oncology, cardiovascular diseases, and neurodegenerative conditions.
Isomorphic Labs, which was spun out from Google’s AI research arm, Google DeepMind, in 2021, is harnessing the power of AI to revolutionize the drug discovery process. Hassabis, who is also the CEO of Google DeepMind, shared that while traditional drug discovery typically takes five to ten years to bring a new drug to market, AI could drastically reduce that time, potentially accelerating the process by as much as ten times. This breakthrough could signal a “revolution in human health,” as Hassabis put it, greatly improving the efficiency and accessibility of life-saving treatments.
In his interview with The Financial Times at the World Economic Forum, Hassabis further explained that the AI drug discovery process, which Isomorphic Labs is pioneering, aims to streamline and enhance the drug development pipeline. He said the team is already working on multiple drug development programs in collaboration with major pharmaceutical companies such as Eli Lilly and Novartis, two industry giants eager to leverage AI to reduce the high costs and time required for traditional drug development.
Additionally, Hassabis discussed the role of AI in accelerating innovation across the pharmaceutical industry. Isomorphic Labs’ approach involves using AI algorithms to predict molecular structures, interactions, and other factors that are critical to drug development, greatly reducing the guesswork involved in the discovery process. This is expected to result in more targeted and effective treatments, especially for diseases with limited treatment options.
The announcement also highlights Isomorphic Labs’ growing potential and its increasing influence within the pharmaceutical industry. In addition to its AI drug discovery programs, Hassabis shared that Google DeepMind’s Project Astra, an AI assistant prototype, is expected to roll out to consumers later in 2025. This further underscores the rapid pace at which AI is being integrated into various sectors, from healthcare to technology.
Despite the excitement surrounding AI’s role in revolutionizing drug discovery, Hassabis also acknowledged the ethical and safety concerns associated with the rapid advancement of AI technologies. He called for a more cautious approach to the development of Artificial General Intelligence (AGI) — the next frontier in AI, capable of mimicking all human cognitive functions. He warned that without proper regulation and safeguards, the unchecked development of AGI could pose significant risks, including the potential for misuse by malicious actors. Hassabis stressed the importance of international coordination among AI developers to ensure the technology is deployed safely and ethically.
While the true realization of AGI remains years away, with Hassabis estimating it to be at least five to ten years in the future, his comments highlight the transformative potential of AI, both in healthcare and beyond. With Isomorphic Labs’ groundbreaking efforts in drug discovery, the intersection of AI and medicine could lead to significant advancements in the treatment of some of the most challenging diseases of our time.
This ambitious push into AI-driven drug development aligns with the broader trend of AI technologies being increasingly utilized in various sectors, from finance to healthcare, as companies like Isomorphic Labs and its pharmaceutical partners seek to unlock new opportunities and efficiencies in the race for groundbreaking treatments.
